Figure
(Figure 1.Illustration of the replication-deficient MLVparticlepseudotyped with SARS-CoV-2 Spike protein)
COVID 19 Pseudoviral Particles, 222V Coronavirus Pseudovirus | COVID-19 pseudovirus
SARS-CoV-2 Pseudoviral Particles, 222V
Synonyms
COVID 19 Pseudoviral Particles; 222V Coronavirus; SARS-CoV-2 Pseudoviral Particles; 222V; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Pseudoviral Particles; COVID-19 pseudovirus
Application Notes
Coupled with firefly luciferase kit (Inquire), the Pseudovirus infection generates robust chemiluminescent signals, 1) for screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-614G-A222V.
Assay Protocol
Note: requires a luciferase assay reagent (Inquire)
Cell Infection:
1. Count HEK293-ACE2 cells (MBS434276) to be infected and seed ~20K cells per well into 96-well plates (50 ul per well) DMEM with 10% FC (no antibiotics) or 5K cells per well into 384-well plates (15 ul per well).
2. Culture cells overnight to make sure the cells stably adhere to the plates.
3. On the 2nd day, remove media, add 50 ul SARS-CoV-2 pseudoviral particles into each well (12.5 ul for 384-well plate). Spin at 700 rpm for 15 min at 4°C.
Note: thaw the pseudoviral particles immediately before use (take about 1 hour to thaw in ice) and use it within 2 hours.
4. Incubate for 2 hrs at 37°C.
5. Add 50 ul DMEM with 10% FC into each well (12.5 ul for 384-well plates).
6. Incubate for 48 hrs at 37°C.
Measurement of Luciferase Activity in Infected cells
1. Remove supernatant.
2. Add 100 ul Luciferase assay reagent (20 ul for 384-well plates).
3. Read in a luminescence plate reader, and record the data.
Assay Protocol
Note: requires a luciferase assay reagent (Inquire)
Cell Infection:
1. Count HEK293-ACE2 cells (MBS434276) to be infected and seed ~20K cells per well into 96-well plates (50 ul per well) DMEM with 10% FC (no antibiotics) or 5K cells per well into 384-well plates (15 ul per well).
2. Culture cells overnight to make sure the cells stably adhere to the plates.
3. On the 2nd day, remove media, add 50 ul SARS-CoV-2 pseudoviral particles into each well (12.5 ul for 384-well plate). Spin at 700 rpm for 15 min at 4°C.
Note: thaw the pseudoviral particles immediately before use (take about 1 hour to thaw in ice) and use it within 2 hours.
4. Incubate for 2 hrs at 37°C.
5. Add 50 ul DMEM with 10% FC into each well (12.5 ul for 384-well plates).
6. Incubate for 48 hrs at 37°C.
Measurement of Luciferase Activity in Infected cells
1. Remove supernatant.
2. Add 100 ul Luciferase assay reagent (20 ul for 384-well plates).
3. Read in a luminescence plate reader, and record the data.
Features
• Robust: Excellent signal to noise (basal) ratio
• Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
• Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
Contents
10 ml (2 tubes, 5 mL/tube), for 2 multi-well plates
Shipping Note
MBS434282 is available for shipment in the United States, Canada and European countries. Please inquire for shipment to other countries.
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
Preparation and Storage
Ships on dry ice. Store at -70°C
Figure
(Figure 1.Illustration of the replication-deficient MLVparticlepseudotyped with SARS-CoV-2 Spike protein)
Figure
(Figure 1.Illustration of the replication-deficient MLVparticlepseudotyped with SARS-CoV-2 Spike protein)
Testing Data
(Figure 2. Pseudoviral Particle (PP) Infection Assays. (-):the negativecontrol(Cat.# MBS434280); SARS2-CoV-2-614G-A222V: the PP pseudotyped with the 222V 614G spike protein (Cat.# MBS434282).)
Testing Data
(Figure 2. Pseudoviral Particle (PP) Infection Assays. (-):the negativecontrol(Cat.# MBS434280); SARS2-CoV-2-614G-A222V: the PP pseudotyped with the 222V 614G spike protein (Cat.# MBS434282).)
Related Product Information for COVID-19 pseudovirus
It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as the entry receptor and human proteases as the entry activators. The virus surface spike (S) protein mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to the receptor human ACE2 (hACE2) through its receptor-binding domain (RBD) and is proteolytically activated by human proteases.
Our SARS-CoV-2 Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus entry assay for SARS-CoV-2 as the S protein mediated cell entry can be conveniently measured via the luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
A new SARS-CoV-2 strain with an amino acid change at position 222 from Ala to Val besides the change at position 614 from Asp to Gly in the viral S protein predominated over time in locales where it was found. To support the study of this new SARS-CoV-2 strain, we established the SARS-CoV-2-614G-A222V Pseudoviral Particles with the spike protein carrying the 222V and 614G genotype (Genbank Accession #QHD43416.1, p.222A->V, p.614D->G)
Our SARS-CoV-2 Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus entry assay for SARS-CoV-2 as the S protein mediated cell entry can be conveniently measured via the luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
A new SARS-CoV-2 strain with an amino acid change at position 222 from Ala to Val besides the change at position 614 from Asp to Gly in the viral S protein predominated over time in locales where it was found. To support the study of this new SARS-CoV-2 strain, we established the SARS-CoV-2-614G-A222V Pseudoviral Particles with the spike protein carrying the 222V and 614G genotype (Genbank Accession #QHD43416.1, p.222A->V, p.614D->G)
NCBI and Uniprot Product Information
Similar Products
Product Notes
The COVID-19 (Catalog #AAA434282) is a Pseudovirus and is intended for research purposes only. The product is available for immediate purchase. Coupled with firefly luciferase kit (Inquire), the Pseudovirus infection generates robust chemiluminescent signals, 1) for screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-614G-A222V. Assay Protocol Note: requires a luciferase assay reagent (Inquire) Cell Infection: 1. Count HEK293-ACE2 cells (MBS434276) to be infected and seed ~20K cells per well into 96-well plates (50 ul per well) DMEM with 10% FC (no antibiotics) or 5K cells per well into 384-well plates (15 ul per well). 2. Culture cells overnight to make sure the cells stably adhere to the plates. 3. On the 2nd day, remove media, add 50 ul SARS-CoV-2 pseudoviral particles into each well (12.5 ul for 384-well plate). Spin at 700 rpm for 15 min at 4°C. Note: thaw the pseudoviral particles immediately before use (take about 1 hour to thaw in ice) and use it within 2 hours. 4. Incubate for 2 hrs at 37°C. 5. Add 50 ul DMEM with 10% FC into each well (12.5 ul for 384-well plates). 6. Incubate for 48 hrs at 37°C. Measurement of Luciferase Activity in Infected cells 1. Remove supernatant. 2. Add 100 ul Luciferase assay reagent (20 ul for 384-well plates). 3. Read in a luminescence plate reader, and record the data. Researchers should empirically determine the suitability of the COVID-19 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "COVID 19 Pseudoviral Particles, 222V Coronavirus, Pseudovirus" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
